Fact Checks

Publish Date
Fact Check: Debunking the Patent “Evergreening” Myth

On April 16, the R Street Institute hosted a congressional briefing entitled “The Hidden Tax: How Bad Patents Drive Up Drug Prices...

Fact Check: The ETHIC Act Targets a Problem That Doesn’t Exist

Congress is considering a bill, the Eliminating Thickets to Increase Competition (ETHIC) Act, that would undermine innovation by preventing patent owners from...

Fact Check: Limiting Injunctive Relief Harms, Not Helps, Inventors

Among the most consequential foreign policy developments is the European Union’s (EU’s) consideration of policies that could limit access to injunctive relief....

Fact Check: The NO FAKES Act Won’t Stifle Innovation — It Will Protect It

The rapid advancement of artificial intelligence has given creators and inventors new technological tools to enhance their work — but it has...

Fact Check: Debunking The Myth of “Evergreening” and “Patent Thicketing”

Former Federal Trade Commission Chair Lina Khan recently appeared on The Weekly Show with Jon Stewart, where their discussion revived familiar tropes...

Fact Check: What Critics Get Wrong About the Patent Eligibility Restoration Act

A coalition of anti-patent groups — including the R Street Institute, the Electronic Frontier Foundation, Public Knowledge, and others — recently sent...

Fact Check: Weakening the patent system won’t lower prices for patients. It would undermine medical progress.

In a recent STAT article, I-MAK CEO Tahir Amin argues that abuses of the patent system are leading to higher drug costs....

Fact Check: The Data Doesn’t Support the Existence of So-Called Patent “Thickets”

Several academic authors recently published an article in Health Affairs Forefront advising policymakers in Congress and at the USPTO on the best...

Fact Check: The Myth of So-Called “Royalty Free” and “Open” Standards

The word “open” has become increasingly misused in the world of technology standards. In policy and antitrust terms, an open standard is...

Infographics & Fact Sheets
Myths vs. Facts: The Patent Eligibility Restoration Act (PERA) – Software and Technology
Infographics & Fact Sheets
Myths vs. Facts: The Patent Eligibility Restoration Act (PERA) – Diagnostics and Life Sciences
Fact Check: Separating Fact From Fiction in Recent FTC/DOJ Listening Sessions on Patents in the Drug Industry

Myths about how patent rights affect competition within the drug industry remain a pressing issue for innovators. Although strong patents play a...

Blog:

Blog, Fact Checks:

Fact Check: The USPTO’s Proposed Requirement for Filing Terminal Disclaimers Would Weaken Patent Rights,

08/28/2024

Blog:

Blog, Fact Checks:

The SHOP SAFE Act Would Improve Consumers’ Online Shopping Experience,

07/19/2024

Blog:

Blog, Fact Checks:

Fact Check: Patents Are Not To Blame for High Drug Prices,

06/26/2024

Blog:

Blog, Fact Checks:

Fact Check: Price Controls Would Not Make Diabetes Treatments More Accessible,

05/24/2024

Blog:

Blog, Fact Checks:

Fact Check: The Patent Eligibility Restoration Act Would Not Make Certain Inventions Automatically Patentable,

04/25/2024

Blog:

Blog, Fact Checks:

Fact Check: The WHO Draft Treaty Would Sabotage Pandemic Preparedness,

03/26/2024

Blog:

Blog, Fact Checks:

Fact Check: The Patent Eligibility Restoration Act Would Promote Medical Innovation,

02/14/2024

Blog:

Blog, Fact Checks:

Misusing the Bayh-Dole Act’s March-In Rights is Not an Effective Way to Reduce Drug Prices,

01/29/2024

Blog:

Blog, Fact Checks:

Fact Check: The PREVAIL Act Would Not Protect “Bad” Patents,

12/20/2023

Blog:

Blog, Fact Checks:

The SHOP SAFE Act Would Benefit Consumers and Small Businesses,

11/27/2023

Blog:

Blog, Fact Checks:

Fact Check: PTAB Reform Would Benefit, Not Harm, Small Inventors,

10/20/2023

Blog:

Blog, Fact Checks:

Fact Check: “Reasonable Pricing” Policies Do Not Promote Innovation,

09/22/2023

Scroll to Top